![](/img/cover-not-exists.png)
Rationale and design of a multicentre, randomized, placebo-controlled trial of mirabegron, a Beta3-adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease Beta3-left ventricular hypertrophy (Be
Pouleur, Anne-Catherine, Anker, Stefan, Brito, Dulce, Brosteanu, Oana, Hasenclever, Dirk, Casadei, Barbara, Edelmann, Frank, Filippatos, Gerasimos, Gruson, Damien, Ikonomidis, Ignatios, Lhommel, RenauLanguage:
english
Journal:
ESC Heart Failure
DOI:
10.1002/ehf2.12306
Date:
June, 2018
File:
PDF, 430 KB
english, 2018